By Daniel Webster, dWeb.News Publisher
Las Vegas, USA, Oct. 14, 2021 (GLOBE NEWSWIRE) — Seborrhoeic Dermatitis Pipeline: Pipeline Review, Novel and Emerging Therapeutic Drugs, Ongoing Clinical Trials Analysis, and Key Pharma Players| DelveInsight
Around 5+ key companies are developing therapies for Seborrhoeic Dermatitis, with Arcutis Biotherapeutics having its product (ARQ-154) in the Phase III stage of development.
DelveInsight’s ‘Seborrhoeic Dermatitis Pipeline Insight 2021’ report provides comprehensive details of available, marketed, and pipeline therapies in different phases of clinical development, key companies working to advance the pipeline space, and future growth potential of the Seborrhoeic Dermatitis pipeline domain. The report also highlights the dormant, inactive, abandoned drugs agents and unmet needs with respect to the development of Seborrhoeic Dermatitis.
Some of the key takeaways from the Seborrhoeic Dermatitis Pipeline report:
- DelveInsight’s Seborrhoeic Dermatitis Pipeline analysis portrays the domain with 5+ active players and 5+ pipeline therapies under different phases of development.
- Some of the major pharmaceutical companies are developing potential drug candidates to improve the Seborrhoeic Dermatitis treatment scenario, such as MatriSys Bio, Amorepacific, DermBiont, Arcutis Biotherapeutics, Inc, Astion Pharma A/S, Quark Pharmaceuticals, and others.
- Key Seborrhoeic Dermatitis pipeline drug candidates/therapies such as MSB-7154, PAC 14028, DBI-002, ARQ-154, and others are under investigation in different phases of clinical trials.
- In July 2021, Arcutis Biotherapeutics announced enrollment of the first patient in its single pivotal Phase 3 clinical trial evaluating topical roflumilast foam (ARQ-154) as a potential treatment for seborrheic dermatitis. Roflumilast foam is a once-daily topical foam formulation of roflumilast, a highly potent and selective phosphodiesterase type 4 (PDE4) inhibitor.
Request for a Sample to know which pharma company is forecasted to lead the Seborrhoeic Dermatitis pipeline in the coming years @ Seborrhoeic Dermatitis Emerging Therapies and Forecast
The Seborrhoeic Dermatitis pipeline report lays down detailed profiles of the pipeline assets, inactive and dormant assets, comparative analysis of clinical and non-clinical stage Seborrhoeic Dermatitis products, comprehensive assessment of driving and restraining factors, along with the opportunities and risks in the Seborrhoeic Dermatitis pipeline landscape.
Seborrhoeic dermatitis, also known as seborrhoea, is a long-term skin disorder. It is a skin condition that causes scaly patches and red skin, mainly on the scalp. Seborrhoea also occurs on oily areas of the body, such as the face, sides of the nose, eyebrows, ears, eyelids, upper chest, and back. In addition to scaly patches and red skin, Seborrhoeic Dermatitis can cause stubborn dandruff. The cause of Seborrhoeic Dermatitis is unknown but many researchers suggest that it may be related to a yeast (fungus) called Malassezia that is in the oil secretion on the skin or an irregular response of the immune system.
Seborrheic Dermatitis signs and symptoms may include skin flakes (dandruff) on scalp, hair, eyebrows, beard, or moustache, patches of greasy skin covered with flaky white or yellow scales or crust on the scalp, face, sides of the nose, eyebrows, ears, eyelids, chest, armpits, groin area or under the breasts, red skin, and itching. Medicated shampoos, creams, and lotions are the main treatments for Seborrheic Dermatitis.
Discover more about the therapeutic scenario in Seborrhoeic Dermatitis @ Seborrhoeic Dermatitis Emerging Therapies, Treatments, and Ongoing Clinical Trials
Seborrhoeic Dermatitis Pipeline Drugs
|MSB-7154||MatriSys Bio||Preclinical||Bacteria replacements; Microbiome modulators||Topical|
|PAC 14028||Amorepacific||Phase II||TRPV1 receptor antagonists||Topical|
|DBI-002||DermBiont||Phase II||Microbiome modulators||Topical|
|ARQ-154||Arcutis Biotherapeutics, Inc||Phase III||Type 4 cyclic nucleotide phosphodiesterase inhibitors||Topical|
Learn more about major pipeline therapies in the Seborrhoeic Dermatitis domain @ Seborrhoeic Dermatitis Key Companies and Pipeline
Seborrhoeic Dermatitis Therapeutics Assessment
The Seborrhoeic Dermatitis Pipeline report proffers an integral view of the Seborrhoeic Dermatitis emerging novel therapies segmented by Stage, Product Type, Route of Administration, Molecule Type, and Mechanism of Action.
By Product Type
- Phase I
- Phase II
- Phase III
By Route of Administration
By Molecule Type
- Gene therapy
- Stem cell therapy
- Small molecules
By Mechanism of Action
- TRPV1 receptor antagonists
- Type 4 cyclic nucleotide phosphodiesterase inhibitors
- Microbiome modulators
Scope of the Seborrhoeic Dermatitis Pipeline Report
- Coverage: Global
- Major Players: MatriSys Bio, Amorepacific, DermBiont, Arcutis Biotherapeutics, Inc, Astion Pharma A/S, Quark Pharmaceuticals, and others.
- Key Seborrhoeic Dermatitis Pipeline Therapies: MSB-7154, PAC 14028, DBI-002, ARQ-154 among others.
For rich insights into therapeutic assessment and emerging pipeline drugs, visit @ Seborrhoeic Dermatitis Emerging Novel Therapies
Table of Contents
|3||Seborrhoeic Dermatitis: Overview|
|4||Seborrhoeic Dermatitis Analytical Perspective In-depth Commercial Assessment|
|6||Late Stage Products (Phase III)|
|7||Mid Stage Products (Phase II)|
|8||Early Stage Products (Phase I & I/II))|
|12||Company-University Collaborations (Licensing/Partnering) Analysis|
|13||Seborrhoeic Dermatitis Key Companies|
|14||Seborrhoeic Dermatitis Key Products|
|15||Seborrhoeic Dermatitis- Market Drivers and Barriers|
|16||Seborrhoeic Dermatitis- Unmet Needs|
|17||Seborrhoeic Dermatitis Future Perspectives and Conclusion|
|18||Seborrhoeic Dermatitis Analyst Views|
Discover more about offerings of Seborrhoeic Dermatitis report @ Seborrhoeic Dermatitis Pipeline Landscape
Track and evaluate a candidate’s clinical development journey here @ Profiling and Comparative Therapeutic Assessment
DelveInsight’s “Allergic Conjunctivitis – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Allergic Conjunctivitis, historical and forecasted epidemiology, market trends, market share of the individual therapies, current and forecasted Allergic Conjunctivitis market, drivers and barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
DelveInsight’s “T Type Calcium Channel Antagonists – Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in T Type Calcium Channel Antagonists pipeline landscape, covers the pipeline drug profiles, including clinical and non-clinical stage products, therapeutics assessment by product type, stage, route of administration, treatments, key companies including Bial, Synokem Pharmaceuticals, Neurocrine Biosciences, Praxis Precision Medicines, Sihuan Pharmaceutical Holdings Group, Cellix Bio, Maruho, DermaXon, and several others.
DelveInsight’s “Chronic Hand Eczema – Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Chronic Hand Eczema pipeline landscape covering pipeline drug profiles, clinical and non-clinical stage products, treatments, key companies including LEO Pharma, Asana BioSciences, Arcutis, and many others.
“Hepatic – Colorectal Metastasis Pipeline Insights, 2021” report by DelveInsight outlays comprehensive insights of present clinical development pipeline scenario and growth prospects across the Hepatic – Colorectal Metastasis market.
“Bunion Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present clinical development scenario including mechanism of action of the drug, clinical studies, Bunion collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details as well as growth prospects across the Bunion market.
DelveInsight’s “Persistent Corneal Epithelial Defects (PEDs) – Market Insights, Epidemiology, and Market Forecast – 2030” report provides a detailed overview of the disease. Key companies include Dompe Farmaceutici, OcuNexus Therapeutics, Eyevance Pharmaceuticals, Noveome Biotherapeutics, RegeneRx Biopharmaceuticals, Recordati Rare Diseases, Mimetech, and others are developing Persistent Epithelial Defect therapies.
DelveInsight’s “Alzheimer’s Disease Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of Alzheimer’s Disease, historical and forecasted epidemiology as well as the Alzheimer’s disease market trends, current treatment practices, emerging drugs, Alzheimer’s Disease market share of the individual therapies, current and forecasted Alzheimer’s Disease market.
DelveInsight’s, “Huntington’s Disease – Pipeline Insight, 2021,” report offers rich insights into epidemiology, treatments, pipeline therapies, and key companies including Prilenia Therapeutics, Ionis Pharmaceuticals, Annexon, Vaccinex, Neurocrine Biosciences, EIP Pharma, SAGE Therapeutics, Celon Pharma, PTC Therapeutics, WaVe life Sciences, Amsterdam Molecular Therapeutics, Novartis, Retrotope, Hope Biosciences, Stealth BioTherapeutics, Luye Pharma Group, Neurimmune Therapeutics, SOLA Biosciences, and several others.
Browse Through Our Blog Posts
Awareness about any condition is as important as treating the condition itself. Similar is the case with, Rosacea, a characteristic inflammatory condition affecting the skin especially the face resulting in facial erythema or redness. Around one in 10 people in the world is affected by rosacea.
Cancer today is one of the most deadly diseases worldwide, causing a significant burden in terms of mortality, years of life lost, and disability as compared to other diseases.
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
For more insights, visit Pharma, Healthcare, and Biotech News
For more dWeb.News Business News: https://dweb.news/news-sections/business-news/
ALISO VIEJO, Calif.–(BUSINESS WIRE)–BrainChip Holdings Ltd (ASX: BRN), (OTCQX: BRCHF), a leading provider of ultra-low power high performance artificial intelligence technology, today announced that Chief Development Officer Anil Mankar will present “Intelligent Edge AI: The Future is Now” at the Linley Fall Processor Conference 2021 in the Hyatt Regency Hotel in Santa Clara, California, October…
Artificial intelligence (AI), which has seen rapid growth over the past few years, is mainly due to the development of deep neural networks and artificial intelligence computing technology. Experts believe that there will come a time when artificial intelligence will exceed human intelligence, or be able to do many tasks better than humans.
WASHINGTON – As part of its mission to recruit diverse cybersecurity talent and build the workforce of the future, the Cybersecurity and Infrastructure Security Agency (CISA) has awarded $2 million to two innovative organizations for development of cyber workforce training programs. The NPower and CyberWarrior organizations, which received the awards, will focus on the unemployed…
The Moscow Metro on Friday rolled out what authorities have touted as the world’s first fare payment system based on facial recognition technology. The cashless, cardless and phone-less system, called ‘Face Pay,’ has been fitted at special turnstiles across the Russian capital’s more than 240 metro stations. “To enter the metro, passengers won’t need a…
Most Popular Articles on dWeb.News
- Beeco Lab to Debut New Kitchen Composter Created for Every Home
- Front Page: US Seeks To Contain Beijing Anger After Biden Vows Taiwan Defense
- Health: These New Hoka One Ones Are Perfect for Marathon Training
- Dunzo Is Building India’s Largest Quick Commerce Platform with Dunzo Daily
- BUSINESS: Moonbug Announces A New Character Meekah To Join Blippi Universe
- GAMING: How To Unlock The LAPA SMG For CoD: Warzone And Black Ops Cold War